Form D · Biotechnology
SYNTIS BIO, INC.
Boston, MA · CIK 0001943061
Offering snapshot reported Jul 2, 2025 · SEC filing
- Reported sold
- $25M Offering amount: $26.5M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 2, 2025 | Initial | $24,983,429 | No comparison | 12 | SEC filing |
| Jan 27, 2025 | Initial | $6,316,555 | No comparison | 9 | SEC filing |
| Jan 17, 2023 | Amendment | $15,372,179 | $4,182,194vs Aug 17, 2022 | 15 | SEC filing |
| Aug 17, 2022 | Initial | $11,189,985 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-550616
Source: Form D, filed Jul 2, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Teymour Boutros Ghali | Director |
| Rahul Dhanda | Director, Executive |
| Robert Langer | Director |
| Martin Madaus | Director |
| Michael Nannizzi | Director |
| Carlo Giovanni Traverso | Director |
| Carlo Giovanni Traverso | Director |
| Chenny Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
135 Morrissey Blvd Suite 101 A
Boston, MA, 02125
Boston, MA, 02125